EMA to Grant Initial Authorization to Gilead's Remdesivir for COVID-19 is Imminent
Shots:
- EMA’s head Guido Rasi stated that an initial authorization could be granted to the Gilead’s remdesivir as a potential treatment for COVID-19. The conditional MAA is expected to be issued in coming days
- Earlier- the EMA has recommended the compassionate use of remdesivir- which allows a drug to be administered to patients even before it has been fully authorized
- Additionally- Guido Rasi stated that other possible treatments that may be available fast are mAbs- that can neutralize the SARS-CoV-2
Click here to read full press release/ article
Ref: Reuters | Image:Gilead
Related News: EMA’s CHMP Recommends Compassionate Use of Gilead’s Remdesivir for COVID-19
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
